Preclinical studies have demonstrated that dual blockade of PD-1 and CTLA-4, combined with the GM-CSF gene-transfected GVAX vaccine, effectively induced tumor rejection and restored T-cell activity in CRC murine models (261). Here, PDCD1 is linked to neoplasm.